The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001).
M. Ueno
No relevant relationships to disclose
S. Ohkawa
No relevant relationships to disclose
K. Sugimori
No relevant relationships to disclose
S. Kobayashi
No relevant relationships to disclose
T. Kaneko
No relevant relationships to disclose
M. Taguri
No relevant relationships to disclose
S. Morita
No relevant relationships to disclose